Lactoferrin-Anchored Tannylated Mesoporous Silica Nanomaterials for Enhanced Osteo-Differentiation Ability
- Authors
- Noh, Sung Hyun; Jo, Han-Saem; Choi, Somang; Song, Hee Gyeong; Kim, Hak-Jun; Kim, Keung Nyun; Kim, Sung Eun; Park, Kyeongsoon
- Issue Date
- 1월-2021
- Publisher
- MDPI
- Keywords
- mesoporous silica nanomaterials; lactoferrin; adipose-derived stem cells; osteo-differentiation ability
- Citation
- PHARMACEUTICS, v.13, no.1, pp.1 - 13
- Indexed
- SCIE
SCOPUS
- Journal Title
- PHARMACEUTICS
- Volume
- 13
- Number
- 1
- Start Page
- 1
- End Page
- 13
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/50224
- DOI
- 10.3390/pharmaceutics13010030
- ISSN
- 1999-4923
- Abstract
- In the present study, we created lactoferrin-anchored mesoporous silica nanomaterials with absorbed tannic acid (LF/TA-MSNs) and evaluated the effect of these LF/TA-MSNs on the in vitro osteo-differentiation ability of adipose-derived stem cells (ADSCs) by testing alkaline phosphatase (ALP) level, calcium accumulation, and expression of osteo-differentiation-specific genes, including osteocalcin (OCN) and osteopontin (OPN). Both bare MSNs and LF/TA-MSNs exhibited round nano-particle structures. The LF/TA-MSNs demonstrated prolonged LF release for up to 28 days. Treatment of ADSCs with LF (50 mu g)/TA-MSNs resulted in markedly higher ALP level and calcium accumulation compared to treatment with LF (10 mu g)/TA-MSNs or bare MSNs. Furthermore, LF (50 mu g)/TA-MSNs remarkably increased mRNA levels of osteo-differentiation-specific genes, including OCN and OPN, compared to MSNs or LF (10 mu g)/TA-MSNs. Together, these data suggest that the ability of LF/TA-MSNs to enhance osteo-differentiation of ADSCs make them a possible nanovehicle for bone healing and bone regeneration in patients with bone defect or disease.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.